Keywords

• Fevipiprant
• high purity
• NVP-QAW039;Fevipiprant(NVP-QAW039);QAW039;Fevipiprant (QAW039)

Quick Details

• ProName: Fevipiprant
• CasNo: 872365-14-5
• Molecular Formula: C19H17F3N2O4S
• Appearance: light yellow
• Application: for lab use only
• ProductionCapacity: Metric Ton/Day
• Purity: 98% by HPLC
• LimitNum: 1 Milligram

Superiority

Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonistof the prostaglandin D2 receptor 2 (DP2 or CRTh2)

As of 2016, it is in Phase III[4] clinical trials for the treatment of asthma.[5]

Novartis is developing fevipiprant, a prostaglandin D2 receptor (PD2/CRTh2) antagonist, as an oral capsule formulation for treating asthma and moderate to severe atopic dermatitis.

Details